<DOC>
	<DOCNO>NCT02704338</DOCNO>
	<brief_summary>Separated expand CD4+CD25+CD127- Tregs peripheral blood autoimmune hepatitis patient administrate cell ( 5 x 106 cells/kg ) patient .</brief_summary>
	<brief_title>Safety Efficacy Study Regulatory T Cells Treating Autoimmune Hepatitis</brief_title>
	<detailed_description>The trial carry autoimmune patient . The investigator isolate CD4 ( cluster differentiation ) +CD25 ( cluster differentiation25 ) +CD127 ( cluster differentiation127 ) - Tregs patient , expand IL ( interleukin ) -2 retinoid acid anti-CD3 ( cluster differentiation 3 ) /CD28 ( cluster differentiation 28 ) bead . The patient subsequently treat single infusion CD4+CD25+CD127- Tregs ( 10-20 x 106 cells/kg ) . In clinical trial , investigator monitor number Tregs patient different period , test suppressive function vitro . Also function biopsy liver process determine efficacy Treg therapy .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<criteria>1 . Written inform consent 2 . Autoimmune hepatitis ( accord criterion define international autoimmune hepatitis Group , Hepatology , 2008 ; 48:169176 ) 3 . Negative pregnancy test 4 . Moderately active disease standard treatment 1 . Hepatocellular carcinoma Malignancies 2 . Pregnant lactate woman 3 . Vital organ failure ( Cardiac , Renal Respiratory , et al ) 4 . Sepsis 5 . Active thrombosis portal hepatic vein 6 . Concomitant psychiatric disease chronic illness drugabuse could interfere ability comply protocol give inform consent 7 . Surgery last 2 month surgery plan study , 8 . Participation biomedical research last 3 month plan study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Autoimmune Diseases , Treg</keyword>
</DOC>